Paula Cramer, MD, from the University Hospital of Cologne, Cologne, Germany, discusses the CLL2-BAG trial, a Phase II study evaluating the effectiveness of a sequential treatment involving the administration of bendamustine, followed by a combination of the Bcl2 antagonist, venetoclax, and the anti-CD20 antibody, obinutuzumab, in treating patients with chronic lymphocytic leukemia (CLL). Here, she states that half of the patients in the trial have ceased further treatment due to achieving complete remission and MRD negativity. She hopes that continuous follow-up will show further increasing MRD negativity, which would suggest that treatment can be stopped in the case of complete remission. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.

свернуть